Prospects for Diminishing the Impact of Nonamyloid Small-Vessel Diseases of the Brain
Small-vessel diseases (SVDs) of the brain are involved in about one-fourth of ischemic strokes and a vast majority of intracerebral hemorrhages and are responsible for nearly half of dementia cases in the elderly. SVDs are a heavy burden for society, a burden that is expected to increase further in the absence of significant therapeutic advances, given the aging population. Here, we provide a critical appraisal of currently available therapeutic approaches for nonamyloid sporadic SVDs that are largely based on targeting modifiable risk factors. We review what is known about the pathogenic mechanisms of vascular risk factor-related SVDs and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most frequent hereditary SVD, and elaborate on two mechanism-based therapeutic approaches worth exploring in sporadic SVD and CADASIL. We conclude by discussing opportunities and challenges that need to be tackled if efforts to achieve significant therapeutic advances for these diseases are to be successful.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
---|---|
Enthalten in: |
Annual review of pharmacology and toxicology - 60(2020) vom: 06. Jan., Seite 437-456 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Joutel, Anne [VerfasserIn] |
---|
Links: |
---|
Themen: |
CADASIL |
---|
Anmerkungen: |
Date Completed 11.11.2020 Date Revised 11.11.2020 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1146/annurev-pharmtox-010818-021712 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM300350295 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM300350295 | ||
003 | DE-627 | ||
005 | 20231225102332.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1146/annurev-pharmtox-010818-021712 |2 doi | |
028 | 5 | 2 | |a pubmed24n1001.xml |
035 | |a (DE-627)NLM300350295 | ||
035 | |a (NLM)31425001 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Joutel, Anne |e verfasserin |4 aut | |
245 | 1 | 0 | |a Prospects for Diminishing the Impact of Nonamyloid Small-Vessel Diseases of the Brain |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.11.2020 | ||
500 | |a Date Revised 11.11.2020 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Small-vessel diseases (SVDs) of the brain are involved in about one-fourth of ischemic strokes and a vast majority of intracerebral hemorrhages and are responsible for nearly half of dementia cases in the elderly. SVDs are a heavy burden for society, a burden that is expected to increase further in the absence of significant therapeutic advances, given the aging population. Here, we provide a critical appraisal of currently available therapeutic approaches for nonamyloid sporadic SVDs that are largely based on targeting modifiable risk factors. We review what is known about the pathogenic mechanisms of vascular risk factor-related SVDs and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), the most frequent hereditary SVD, and elaborate on two mechanism-based therapeutic approaches worth exploring in sporadic SVD and CADASIL. We conclude by discussing opportunities and challenges that need to be tackled if efforts to achieve significant therapeutic advances for these diseases are to be successful | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 4 | |a CADASIL | |
650 | 4 | |a NOTCH3 | |
650 | 4 | |a endothelial dysfunction | |
650 | 4 | |a hypertension | |
650 | 4 | |a small-vessel diseases | |
773 | 0 | 8 | |i Enthalten in |t Annual review of pharmacology and toxicology |d 1993 |g 60(2020) vom: 06. Jan., Seite 437-456 |w (DE-627)NLM000078379 |x 1545-4304 |7 nnns |
773 | 1 | 8 | |g volume:60 |g year:2020 |g day:06 |g month:01 |g pages:437-456 |
856 | 4 | 0 | |u http://dx.doi.org/10.1146/annurev-pharmtox-010818-021712 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 60 |j 2020 |b 06 |c 01 |h 437-456 |